Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
Adverum Biotechnologies Inc (NASDAQ: ADVM) received feedback via a
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
Adverum Biotechnologies Inc (NASDAQ: ADVM)
Adverum Biotechnologies Says Finalizing 2-Dose Study Design For Phase 2 Trial Of ADVN-022 In Wet AMD With Intention To Dose First Patient In Q3 2022
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of a review of its ADVM-022 program, outlined
Adverum Biotechnologies Q3 EPS $(0.39) Down From $(0.31) YoY
Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(0.39) per share. This is a 25.81 percent decrease over losses of $(0.31) per share from the same period last year.